{"meshTags":["Glioma","Panniculitis","Proto-Oncogene Proteins B-raf","Adolescent","Indoles","Sulfonamides","Female","Antineoplastic Agents","Humans","Neutrophils","Brain Stem Neoplasms"],"meshMinor":["Glioma","Panniculitis","Proto-Oncogene Proteins B-raf","Adolescent","Indoles","Sulfonamides","Female","Antineoplastic Agents","Humans","Neutrophils","Brain Stem Neoplasms"],"genes":["BRAF"],"organisms":["9606","9606","9606"],"publicationTypes":["Case Reports","Journal Article"],"abstract":"Neutrophilic panniculitis is a rare adverse effect of therapy with selective BRAF inhibitors. We report a case of neutrophilic panniculitis in a 15-year-old girl receiving treatment with vemurafenib for a brainstem glioma. Clinicians should be aware of this rare but important side effect of vemurafenib. This is the first report of neutrophilic panniculitis in a child treated with vemurafenib. ","title":"Vemurafenib-induced neutrophilic panniculitis in a child with a brainstem glioma.","pubmedId":"24602192"}